Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment
Vaccine, ISSN: 0264-410X, Vol: 42, Issue: 22, Page: 126030
2024
- 7Citations
- 15Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef7
- Captures15
- Readers15
- 15
- Mentions1
- News Mentions1
- News1
Most Recent News
Revolutionising RSV infection prevention and control: unveiling new options in the fight against RSV
Respiratory syncytial virus (RSV) is a leading cause of respiratory illness across all age groups, causing significant morbidity and mortality in infants and older individuals
Article Description
Respiratory syncytial virus (RSV) represents a high burden of disease in children and the primary cause of hospitalization, especially in children under 1 year old. In the Valencian Community (Spain), nirsevimab, a long-acting monoclonal antibody, was introduced for the RSV 2023–2024 season as a universal pre-exposure prophylaxis for high-risk children and those under 6 months old. This study examines its impact, coverage, and effectiveness. The campaign achieved 88.5 % coverage and 73.7 % of effectiveness. Analysis of over 27,000 susceptible children (over 24,000 immunized), showed that those immunized exhibited a threefold reduction in RSV incidence compared to non-immunized ones. To prevent one case, the number needed to immunize (NNI) was 63. Hospitalizations due to acute respiratory infections were almost two times lower in immunized children compared to non-immunized ones (0.9 % vs 1.6 %, respectively). These first results showcase the preliminary positive impact of this public health intervention.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0264410X24006571; http://dx.doi.org/10.1016/j.vaccine.2024.05.078; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85195079269&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38834430; https://linkinghub.elsevier.com/retrieve/pii/S0264410X24006571
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know